Gadolinium-Based Contrast Media Nephrotoxicity in Kidney Impairment: The Physio-Pathological Conditions for the Perfect Murder (2021).

Fibrosis

Jan 13

Paper link: https://www.mdpi.com/2077-0383/10/2/271

Authors and Affiliations: Francesca Martino1,2,*, Gianpaolo Amici 3, Mitchell Rosner4, Claudio Ronco1,2 and Giacomo Novara 5,*

1International Renal Research Institute Vicenza (IRRIV), San Bortolo Hospital, 36100 Vicenza, Italy, 2UO Nephrology, Dialysis and Kidney Transplant, San Bortolo Hospital, 36100 Vicenza, Italy, 3UO Nephrology and Dialysis, San Daniele del Friuli and Tolmezzo Hospital, ASUFC, 33038 San Daniele del Friuli, Italy, 4 Division of Nephrology, University of Virginia Health System, Charlottesville, VA 22903, USA,5Department of Surgery, Oncology, and Gastroenterology, Urology Clinic University of Padua, 35124 Padova, Italy

Bridget Belo

Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis (Feb 2021).

Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks (Dec 2020).

Submit any resources that should be included on the site.

Explore Gadolinium 64

Physicians

Donate

This site is also accessible via contrastdie.com

Fair Use Disclaimer
This website features copyrighted material used in accordance with the principles of fair use as outlined in Section 107 of the U.S. Copyright Act. The material is provided to inform, educate, and encourage public discussion on important issues, including health, education, and science. All content is shared with the intent of advancing understanding and fostering meaningful dialogue. This use is non-commercial and aligns with fair use standards for purposes such as research, education, and commentary. If you believe any content on this site infringes on your copyright, please contact us at Contact Us and we will review your concerns promptly.